Japan To Compensate Hepatitis C Victims, Leave Drug Makers Liable (Japan)
This article was originally published in PharmAsia News
Executive Summary
The Japanese government plans to enact legislation early in the new year to compensate some of an estimated 1,000 patients infected with hepatitis C after being given tainted blood products. The proposed bill would let the courts decide who would be eligible, as well as the fate of drug makers responsible for the suspect blood products. Under the bill being discussed by legislators, government compensation would be confined to patients given fibrinogen and hemostatic agents, but not to those infected through transfusions. Prime Minister Yasuo Fukuda apologized in person to four of the 200 people who filed suits. (Click here for more
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.